Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD018
- Development stage
- Preclinical
- Lead developer
- AIDEA PHARMA
- Modality
- Small Molecules
01
Overview
AD018 is a small molecule innovative drug candidate being developed by Jiangsu Aidi Pharmaceutical (also known as Aidea Pharma) for the treatment of stroke, specifically targeting ischemic stroke. Currently in the preclinical stage of development, AD018 is classified as a Class 1 innovative drug in China. It is designed to function as a neuroprotective agent, aiming to mitigate neuronal damage and the inflammatory response that occurs following a cerebrovascular event. The development of AD018 represents Aidea Pharma's strategic expansion into the cardiovascular and cerebrovascular therapeutic space, complementing its established portfolio of anti-HIV medications.
02
Targets
KNG1 (High-molecular-weight kininogen)
Beyond the preview
Go deeper on AD018.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD018.